GET DAILY SIGNALSRedHill Biopharma (RDHL) Portfolio Reset: Shares Down -9.6% as Focus Turns to New GI Products
Key Takeaways
- RedHill Biopharma (RDHL) traded near $0.43 in early November 2026, roughly 9.6% below its level from a month earlier, a modest decline that keeps the trailing 30-day move below the 10% threshold.
- The company completed a sweeping strategic reset, divesting its Talicia business to Apotex while acquiring U.S. commercialization rights to Rebyota and Clenpiq from Ferring.
- Rebyota and Clenpiq are established, FDA-approved gastrointestinal products that generated approximately $37.5 million in combined 2025 net sales.
- RedHill reported no net revenues in the first half of 2026 during the transition, highlighting the near-term reliance on its newly acquired commercial portfolio.
- Pipeline momentum continued with opaganib's FDA rare pediatric disease designation for neuroblastoma and a $2.9 million NCI grant for an oncology combination program.
- As a thinly capitalized specialty biopharma, RedHill faces meaningful execution and financing risks that warrant close monitoring.
- For additional context on valuation and fundamentals, review RDHL's Price Targets, Earnings, and Forecast pages.
- Investors seeking data-driven, automated strategies can also explore curated trading bots on Trending AI Robots.
Where RDHL Stands in the Market Right Now
RedHill Biopharma's American Depositary Shares trade on the Nasdaq as a micro-cap specialty pharmaceutical name, and the stock has exhibited pronounced volatility in recent months. As of early November 2026, RDHL closed near $0.43, down roughly 9.6% from its close approximately one month earlier. That restrained one-month move masks a choppier path, including an intraday spike in early October when shares briefly approached $0.69 on unusually heavy volume before pulling back. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the broader multi-month window, the stock has trended lower from around $0.72 in early September. Small-cap biopharma sentiment remains sensitive to financing announcements, clinical readouts, and commercialization milestones, all of which are central to RedHill's current narrative.
RedHill Biopharma (RDHL) Business Overview and Competitive Position
RedHill Biopharma Ltd. is an Israel-based specialty biopharmaceutical company, founded in 2009 and headquartered in Tel Aviv, with a focus on gastrointestinal, infectious disease, and oncology programs. For years, its commercial identity centered on Talicia, an FDA-approved treatment for Helicobacter pylori infection, alongside earlier rights to Aemcolo for travelers' diarrhea, which were terminated in 2024.
The company has since repositioned its commercial franchise around two larger, established gastrointestinal products. Rebyota is the first and only single-dose, FDA-approved fecal microbiota transplant for the prevention of recurrent Clostridioides difficile infection, while Clenpiq is a ready-to-drink, low-volume colonoscopy bowel preparation. RedHill's development pipeline includes opaganib, a sphingosine kinase-2 inhibitor in oncology and medical countermeasure programs, as well as RHB-102, RHB-204, and RHB-107. Investors follow the stock for its turnaround story, the revenue potential of its new portfolio, and its clinical catalysts.
Recent Developments Driving RDHL
The defining event of the period was RedHill's portfolio reset. In late August 2026, the company divested its 70% interest in Talicia to Apotex for an $18 million upfront payment plus up to $35 million in potential sales milestones. On September 1, 2026, RedHill announced the acquisition of U.S. commercialization rights to Rebyota and Clenpiq from Ferring, two products that together generated about $37.5 million in 2025 net sales.
Financial results for the first half of 2026, reported in late September, showed no net revenues and an operating loss of approximately $4.1 million, reflecting the transition to the new commercial portfolio. In October, RedHill regained ex-North America rights to RHB-102 through a mutual agreement with Hyloris Pharmaceuticals (HYL), and it received a $2.9 million NCI grant to advance an opaganib and CAR T-cell combination in ultra-high-risk multiple myeloma. In early November, the company announced that two independent laboratories confirmed the MAP-killing activity of RHB-204, its Crohn's disease candidate. From what I see, this kind of pipeline update is important because it could influence future catalysts.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary focus is on the successful commercialization and revenue ramp of Rebyota and Clenpiq, which will determine whether the portfolio reset translates into sustainable cash flow. Investors will also monitor opaganib's oncology programs, including the multiple myeloma combination supported by the NCI grant and the potential Priority Review Voucher tied to its rare pediatric disease designation for neuroblastoma.
Additional catalysts include the planned RHB-204 Phase 2 program in Crohn's disease, RHB-102 development for GLP-1/GIP-associated gastrointestinal intolerance, and any partnership or financing activity. Key risks remain financing and dilution, warrant overhang, Nasdaq listing compliance, clinical trial outcomes, and the company's ability to manage a thin cash position while scaling its commercial operations. I'm watching this closely for signs of execution progress.
Exploring Tickeron AI Trading Bots for My Research
In my view, Tickeron’s AI Trading Bots offer a practical way to monitor automated strategies across many tickers without replacing personal analysis. The platform runs hundreds of bots with different risk profiles and timeframes, and reviewing the top performers helps me spot complementary signals for names like RDHL. It serves as one more data point in my process rather than a standalone solution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RDHL in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 22, 2026
RDHL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 43 cases where RDHL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RDHL's RSI Oscillator exited the oversold zone, 41 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 75 cases where RDHL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on RDHL as a result. In 64 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for RDHL just turned positive on November 04, 2026. Looking at past instances where RDHL's MACD turned positive, the stock continued to rise in 25 of 34 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDHL advanced for three days, in 152 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDHL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RDHL entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (42.656) is normal, around the industry mean (7.254). P/E Ratio (-0.001) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (5.974) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. RDHL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RDHL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in acquisition and development of patented formulations
Industry PharmaceuticalsGeneric
Advertisement